AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 338253 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% desoxymethasone cream
Number of subjects: 40
Study 338253 — intervention group
Group type: COMPARATOR
Intervention: 0.05% betamethasone 17,21-dipropionate cream
Number of subjects: 40
Study 31586310 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 92
Study 29473173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen-reduction treatment (using Mirasol or Intercept systems)
Number of subjects: 358
Study 29473173 — intervention group
Group type: COMPARATOR
Intervention: Conventional platelets
Number of subjects: 358
Study 29473173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercept-treated patients
Number of subjects: 358
Study 29473173 — intervention group
Group type: COMPARATOR
Intervention: Mirasol study patients
Number of subjects: 358
Study 26215702 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink N high viscosity cement
Number of subjects: 50
Study 26215702 — intervention group
Group type: COMPARATOR
Intervention: G‐Cem Automix cement
Number of subjects: 50
Study 26215702 — intervention group
Group type: COMPARATOR
Intervention: G‐Cem Automix cement at 37°C
Number of subjects: 50
Study 24874564 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholegrain rye kernel bread (RKB)
Number of subjects: 12
Study 24874564 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled rye kernels (RK)
Number of subjects: 12
Study 24874564 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fermentation of RKB and RK
Number of subjects: 12
Study 24874564 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fermentation of RKB
Number of subjects: 12
Study 22172907 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IFRT) 30 Gy
Number of subjects: 124
Study 22172907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IFRT)
Number of subjects: 124
Study 20127909 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Number of subjects: 101
Study 20127909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy
Number of subjects: 101
Study 20127909 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affectivity and current depression
Number of subjects: 101
Study 20127909 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of cognitive performance
Number of subjects: 101
Study 20127909 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological compromise
Number of subjects: 101
Study 18763255 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 120
Study 18763255 — intervention group
Group type: COMPARATOR
Intervention: Cryostripping
Number of subjects: 120
Study 15785912 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 18
Study 15785912 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 18
Study 15785912 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 18
Study 12849773 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive tasks administered to children with Klinefelter's syndrome (KS)
Number of subjects: 3
Study 12849773 — intervention group
Group type: COMPARATOR
Intervention: Controls matched for age, sex, and intelligence
Number of subjects: 3
Study 10589865 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 seconds rest interval (20 RI)
Number of subjects: 7
Study 10589865 — intervention group
Group type: COMPARATOR
Intervention: 60 seconds rest interval (60 RI)
Number of subjects: 7
Study 8693426 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 100
Study 8693426 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 100
Study 1931401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-naloxone (F-Nal)
Number of subjects: 71
Study 1931401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-normal saline (F-NS)
Number of subjects: 71
Study 1931401 — intervention group
Group type: COMPARATOR
Intervention: Normal saline-naloxone (NS-Nal)
Number of subjects: 71
Study 1931401 — intervention group
Group type: COMPARATOR
Intervention: Normal saline-normal saline (NS-NS)
Number of subjects: 71
Study 6982055 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trifamole (TMP and sulphamoxole)
Number of subjects: 10
Study 6982055 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (TMP and sulphonamide)
Number of subjects: 10
Study 31361837 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention with a 1-page asthma question prompt list
Number of subjects: 359
Study 31361837 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 359
Study 30150464 — intervention group
Group type: EXPERIMENTAL
Intervention: Single i.v. doses of 0.1 to 3 mg/kg of body weight
Number of subjects: 0
Study 30150464 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of treatment with 0.5 or 1.5 mg/kg every 24 h (q24h) over 30 min
Number of subjects: 0
Study 30150464 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg q24h over 60 min
Number of subjects: 0
Study 30150464 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg q12h over 60 min
Number of subjects: 0
Study 30150464 — intervention group
Group type: EXPERIMENTAL
Intervention: Eravacycline
Number of subjects: 0
Study 27117887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release (LAR)
Number of subjects: 7
Study 27117887 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide long-acting release (LAR)
Number of subjects: 7
Study 27117887 — intervention group
Group type: COMPARATOR
Intervention: Transsphenoidal surgery
Number of subjects: 7
Study 27117887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Number of subjects: 7
Study 24247736 — intervention group
Group type: EXPERIMENTAL
Intervention: Phthalate exposure during pregnancy
Number of subjects: 482
Study 22703751 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Fascial Manipulation (OFM)
Number of subjects: 140
Study 22703751 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Control)
Number of subjects: 140
Study 20415898 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (more intensive regimen)
Number of subjects: 0
Study 20415898 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (less intensive regimen)
Number of subjects: 0
Study 20415898 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study 20415898 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0
Study 18613274 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic appendectomy
Number of subjects: 107
Study 16521851 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified oxygenated water (EXP)
Number of subjects: 9
Study 16521851 — intervention group
Group type: COMPARATOR
Intervention: Control water (CON)
Number of subjects: 9
Study 12072852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spinal manipulation
Number of subjects: 36
Study 12072852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spinal manipulation
Number of subjects: 36
Study 10691270 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple regimen (senna syrup, Picolax, Klean Prep)
Number of subjects: 132
Study 10691270 — intervention group
Group type: COMPARATOR
Intervention: Fleet Phospho-soda
Number of subjects: 132
Study 9071429 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg/day orally for 28 days)
Number of subjects: 12
Study 9071429 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (300 mg/day for an additional month)
Number of subjects: 12
Study 9071429 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (for the patient who failed thalidomide therapy)
Number of subjects: 12
Study 9071429 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up to 20 months
Number of subjects: 12
Study 8178700 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' former smoking
Number of subjects: 719
Study 8178700 — intervention group
Group type: EXPERIMENTAL
Intervention: Family characteristics (family disunion, parents' awareness of child's activities)
Number of subjects: 719
Study 8178700 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent model
Number of subjects: 719
Study 3087709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 3087709 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enteral alimentation
Number of subjects: 0
Study 3087709 — intervention group
Group type: COMPARATOR
Intervention: No treatment (placebo)
Number of subjects: 0
Study 31728618 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT with PG2 injection (Astragalus polysaccharides) administered three times per week
Number of subjects: 17
Study 31728618 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT with PG2 injection
Number of subjects: 17
Study 31728618 — intervention group
Group type: COMPARATOR
Intervention: CCRT with placebo
Number of subjects: 17
Study 30396454 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (7-day dosage)
Number of subjects: 563
Study 30396454 — intervention group
Group type: COMPARATOR
Intervention: Long-acting GnRH agonist (single dose)
Number of subjects: 563
Study 28083720 — intervention group
Group type: EXPERIMENTAL
Intervention: Social stressor (Trier Social Stress Test)
Number of subjects: 56
Study 28083720 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 56
Study 25970838 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 84
Study 25970838 — intervention group
Group type: COMPARATOR
Intervention: PLEX
Number of subjects: 84
Study 23910743 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 31
Study 23910743 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 31
Study 20306195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m²
Number of subjects: 42
Study 20306195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m²
Number of subjects: 42
Study 20306195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses (1.0 and 1.3 mg/m²)
Number of subjects: 42
Study 18333598 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) + placement of chlorhexidine chip (PC)
Number of subjects: 11
Study 18333598 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 11
Study 16552342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 36 mg orally twice daily
Number of subjects: 130
Study 16552342 — intervention group
Group type: COMPARATOR
Intervention: Warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0
Number of subjects: 130
Study 12666712 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Functional Loading (IFL) for 422 implants
Number of subjects: 152
Study 12666712 — intervention group
Group type: COMPARATOR
Intervention: Immediate Non-Functional Loading (INFL) for 224 implants
Number of subjects: 152
Study 11967788 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (AT(1)-receptor blocker)
Number of subjects: 0
Study 9375707 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra
Number of subjects: 89
Study 9375707 — intervention group
Group type: COMPARATOR
Intervention: Triglycerides
Number of subjects: 89
Study 10146578 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use 7 French bioptome (Group I)
Number of subjects: 63
Study 10146578 — intervention group
Group type: COMPARATOR
Intervention: Reusable 8 French bioptome (Group II)
Number of subjects: 63
Study 10146578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of single-use bioptome
Number of subjects: 63
Study 10146578 — intervention group
Group type: COMPARATOR
Intervention: Cost of reusable bioptome
Number of subjects: 63
Study 30461202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Number of subjects: 134
Study 30461202 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 134
Study 29110675 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin and lysozyme daily supplement
Number of subjects: 86
Study 29110675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 25463375 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-electrode renal sympathetic denervation (RDN)
Number of subjects: 31
Study 25463375 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 resistant hypertensives matched for office BP)
Number of subjects: 31
Study 25714215 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 30
Study 25714215 — intervention group
Group type: COMPARATOR
Intervention: AAS
Number of subjects: 30
Study 21689116 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal context that supported psychological needs
Number of subjects: 0
Study 21689116 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal context that did not support psychological needs
Number of subjects: 0
Study 21689116 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal conditions that supported psychological needs
Number of subjects: 0
Study 21689116 — intervention group
Group type: COMPARATOR
Intervention: Goal conditions that did not support psychological needs
Number of subjects: 0
Study 20191582 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg administered intravenously every 4 weeks)
Number of subjects: 190
Study 17668880 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha (pegIFN‐alpha) plus ribavirin
Number of subjects: 70
Study 15793107 — intervention group
Group type: EXPERIMENTAL
Intervention: micafungin (12.5 to 200 mg/day)
Number of subjects: 74
Study 15793107 — intervention group
Group type: COMPARATOR
Intervention: normal saline (control)
Number of subjects: 74
Study 12496978 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of distal urethral web
Number of subjects: 0
Study 9814460 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I/99mTc‐sestamibi subtraction SPECT
Number of subjects: 19
Study 7897962 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE
Number of subjects: 120
Study 7897962 — intervention group
Group type: EXPERIMENTAL
Intervention: phaco/suture
Number of subjects: 120
Study 7897962 — intervention group
Group type: EXPERIMENTAL
Intervention: phaco/tunnel
Number of subjects: 120
Study 7897962 — intervention group
Group type: EXPERIMENTAL
Intervention: inexperienced surgeons
Number of subjects: 120
Study 7897962 — intervention group
Group type: EXPERIMENTAL
Intervention: experienced surgeons
Number of subjects: 120
Study 7897962 — intervention group
Group type: COMPARATOR
Intervention: prophylactic medication (levobunolol, acetazolamide, apraclonidine)
Number of subjects: 120
Study 2706176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% halothane
Number of subjects: 40
Study 2706176 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% enflurane
Number of subjects: 40
Study 2706176 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% isoflurane
Number of subjects: 40
Study 2706176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% enflurane
Number of subjects: 40
Study 2706176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% isoflurane
Number of subjects: 40
Study 811704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate (Cyclospasmol), 400 mg four times daily
Number of subjects: 21
Study 811704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30636000 — intervention group
Group type: EXPERIMENTAL
Intervention: High ADHD screening score
Number of subjects: 340
Study 30636000 — intervention group
Group type: COMPARATOR
Intervention: Low ADHD screening score
Number of subjects: 340
Study 30636000 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, motorcycling records, mean of riding hours per day
Number of subjects: 340
Study 30636000 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD screening
Number of subjects: 340
Study 28454807 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support tool (CDS) integrated in electronic health record
Number of subjects: 444347
Study 28454807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDS intervention)
Number of subjects: 444347
Study 26560727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 41
Study 25338498 — intervention group
Group type: EXPERIMENTAL
Intervention: rRT+APG101 (400 mg weekly i.v.)
Number of subjects: 91
Study 25338498 — intervention group
Group type: COMPARATOR
Intervention: rRT (36 Gy; five times 2 Gy per week)
Number of subjects: 91
Study 22311178 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICE program (voluntary after-school program)
Number of subjects: 9528
Study 19530944 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephroscopic stone fragmentation (group 1, n = 22)
Number of subjects: 43
Study 19530944 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopic stone fragmentation (group 2, n = 21)
Number of subjects: 43
Study 17513803 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (1 mg/kg/d orally) plus interferon alfa (3 x 10(6) U subcutaneously three times per week)
Number of subjects: 66
Study 17513803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 66
Study 17513803 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid plus interferon alfa
Number of subjects: 66
Study 15078261 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine (AQ) 10 mg/kg
Number of subjects: 87
Study 15078261 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AR) 4 mg/kg first day then half dose
Number of subjects: 87
Study 15078261 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (AQAR)
Number of subjects: 87
Study 11771678 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (250 mg to 2,000 mg over 10 weeks)
Number of subjects: 10
Study 11771678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 2)
Number of subjects: 10
Study 9684731 — intervention group
Group type: EXPERIMENTAL
Intervention: Met66 residue in K.IV type 10 of apo(a)
Number of subjects: 308
Study 9684731 — intervention group
Group type: EXPERIMENTAL
Intervention: Thr66 residue in K.IV type 10 of apo(a)
Number of subjects: 308
Study 9684731 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic atherosclerosis
Number of subjects: 308
Study 7519567 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) 25 mg
Number of subjects: 53
Study 7519567 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACET) 250 mg
Number of subjects: 53
Study 7519567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Number of subjects: 53
Study 7519567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 2657616 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (800 mg/m2/day) and ticarcillin‐clavulanate
Number of subjects: 14
Study 2657616 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1.2 g/m2/day), amikacin, and ticarcillin
Number of subjects: 14
Study 31987235 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology applied twice a week for 6 weeks (30-40 min per session)
Number of subjects: 63
Study 31987235 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 63
Study 31987235 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 63
Study 31500422 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg orally (days 1-4) + ondansetron 8 mg IV + dexamethasone 20 mg IV (30 minutes before chemotherapy) + dexamethasone 10 mg orally (days 1-4)
Number of subjects: 39
Study 31500422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (days 1-4) + ondansetron 8 mg IV + dexamethasone 20 mg IV (30 minutes before chemotherapy) + dexamethasone 10 mg orally (days 1-4)
Number of subjects: 39
Study 28939492 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-containing wash products
Number of subjects: 154
Study 28939492 — intervention group
Group type: COMPARATOR
Intervention: No-TC-containing wash products
Number of subjects: 154
Study 25799793 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide
Number of subjects: 75
Study 25799793 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide
Number of subjects: 75
Study 25799793 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 75
Study 23800177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose combination therapy (polypill)
Number of subjects: 513
Study 23800177 — intervention group
Group type: COMPARATOR
Intervention: Current care
Number of subjects: 513
Study 22760901 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate IV infusion (2 g)
Number of subjects: 20
Study 22760901 — intervention group
Group type: COMPARATOR
Intervention: Saline IV infusion
Number of subjects: 20
Study 19953931 — intervention group
Group type: EXPERIMENTAL
Intervention: CD147 expression in prostate cancer
Number of subjects: 101
Study 19953931 — intervention group
Group type: COMPARATOR
Intervention: CD147 expression in benign prostatic hyperplasia
Number of subjects: 101
Study 19953931 — intervention group
Group type: COMPARATOR
Intervention: CD147 expression in normal prostate
Number of subjects: 101
Study 19953931 — intervention group
Group type: COMPARATOR
Intervention: CD147 expression in embryonic prostate
Number of subjects: 101
Study 19953931 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of CD147 expression with TNM stage
Number of subjects: 101
Study 19953931 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of CD147 expression with depth of prostatic capsule invasion
Number of subjects: 101
Study 19953931 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of CD147 expression with histological grade
Number of subjects: 101
Study 17888966 — intervention group
Group type: EXPERIMENTAL
Intervention: Single aortic cross‐clamp technique
Number of subjects: 107
Study 17888966 — intervention group
Group type: COMPARATOR
Intervention: Multiple aortic cross‐clamp technique
Number of subjects: 107
Study 17888966 — intervention group
Group type: COMPARATOR
Intervention: Off‐pump CABG
Number of subjects: 107